Au C C, Einsenstein T K
Infect Immun. 1981 Jan;31(1):169-73. doi: 10.1128/iai.31.1.169-173.1981.
We tested the hypothesis that the capacity of subcellular preparations of rough pneumococci to give cross-serotype protection is due to the presence of the pneumococcal Forssman antigen (F-polysaccharide). We found by hemagglutination inhibition that the Forssman antigen is present in the subcellular extracts. However, we concluded that the Forssman antigen is not the protective immunogen in the pneumococcal subcellular preparation, since absorption with sheep erythrocytes failed to remove the protective capacity from antiserum raised against the vaccine. Other evidence mitigating against the pneumococcal Forssman antigen being the protective immunogen included the absence of a detectable hemolytic titer in protective antiserum raised against the subcellular preparation, the failure of high-titered sheep hemolysin to passively protect mice against pneumococcal infection, and the failure of purified F-polysaccharide to immunize mice against pneumococcal infection.
粗糙型肺炎球菌亚细胞制剂产生交叉血清型保护的能力归因于肺炎球菌福斯曼抗原（F-多糖）的存在。我们通过血凝抑制试验发现，福斯曼抗原存在于亚细胞提取物中。然而，我们得出结论，福斯曼抗原不是肺炎球菌亚细胞制剂中的保护性免疫原，因为用绵羊红细胞吸收并不能去除针对该疫苗产生的抗血清的保护能力。其他不利于肺炎球菌福斯曼抗原作为保护性免疫原的证据包括：针对亚细胞制剂产生的保护性抗血清中未检测到溶血效价；高滴度的绵羊溶血素不能被动保护小鼠抵抗肺炎球菌感染；纯化的F-多糖不能使小鼠产生针对肺炎球菌感染的免疫力。
